Jastreboff AM, Kaplan LM, Fras JP, et al
The primary actions of GLP-1 include stimulating insulin secretion from pancreatic beta cells in response to elevated blood glucose (importantly, this insulin release is glucose-dependent, reducing hypoglycaemia risk), suppressing glucagon release (which prevents the liver from producing excess glucose), and slowing gastric emptying
Some observational studies suggest a lower risk of new depression diagnoses among GLP-1 users compared to those taking other diabetes or weight-loss medications
Patients with mild to severe hepatic impairment, those using concurrent OATP1B1 inhibitors, or those who cant tolerate the 100 mg dosage are advised to use eluxadoline 75 mg twice daily (61)
Prevalence and patterns of dietary supplement use in elite Spanish athletes
These are the ones well focus on here